1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,372 | 0,386 | 13:19 | |
| 0,372 | 0,386 | 13:19 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | FibroBiologics, Inc.: FibroBiologics to Present at Bio-Europe 2025 | 1 | GlobeNewswire (USA) | ||
| 26.09. | RedChip Companies, Inc.: BioVie and FibroBiologics Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV | 355 | ACCESS Newswire | ORLANDO, FLORIDA / ACCESS Newswire / September 26, 2025 / RedChip Companies will air interviews with BioVie Inc. (NASDAQ:BIVI) and FibroBiologics, Inc. (Nasdaq:FBLG) on the RedChip Small Stocks, Big... ► Artikel lesen | |
| 23.09. | FibroBiologics, Inc.: FibroBiologics to Present at 2025 Cell & Gene Meeting on the Mesa | 2 | GlobeNewswire (USA) | ||
| 12.09. | FibroBiologics, Inc.: FibroBiologics Leadership Authors Opinion Editorial Highlighting Fibroblast Cells' Therapeutic Advantages Over Traditional Stem Cell Therapies | 2 | GlobeNewswire (USA) | ||
| 12.09. | H.C. Wainwright bestätigt Kaufempfehlung für FibroBiologics und Kursziel von 10 US-Dollar | 5 | Investing.com Deutsch | ||
| 12.09. | FibroBiologics stock price target maintained at $10 by H.C. Wainwright | 1 | Investing.com | ||
| 11.09. | FibroBiologics, Inc.: FibroBiologics Announces Positive IND-Enabling Updates Demonstrating Potential of Fibroblast Spheroids in Chronic-Relapse Psoriasis Treatment | 1 | GlobeNewswire (USA) | ||
| 10.09. | FibroBiologics, Inc.: FibroBiologics Announces Significant Advancements in Bone Marrow Organoid Platform Enabling Development for Cancer and Immune-Related Therapies | 113 | GlobeNewswire (Europe) | HOUSTON, Sept. 10, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the... ► Artikel lesen | |
| FIBROBIOLOGICS Aktie jetzt für 0€ handeln | |||||
| 01.08. | FibroBiologics reports 1H results | 5 | Seeking Alpha | ||
| 31.07. | FibroBiologics, Inc.: FibroBiologics Reports Second Quarter 2025 Financial Results and Provides Corporate Update | 197 | GlobeNewswire (Europe) | HOUSTON, July 31, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development... ► Artikel lesen | |
| 31.07. | FibroBiologics, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 28.07. | FibroBiologics files patent for multipotent cell generation method | 2 | Investing.com | ||
| 28.07. | FibroBiologics, Inc.: FibroBiologics Files Patent for Methods of Generating Multipotent Cells from Donor Tissue for Clinical Applications | 2 | GlobeNewswire (USA) | ||
| 18.07. | FibroBiologics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 11.07. | RedChip Companies, Inc.: Brag House and FibroBiologics Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV | 484 | ACCESS Newswire | ORLANDO, FL / ACCESS Newswire / July 11, 2025 / RedChip Companies will air interviews with Brag House Holdings, Inc. (NASDAQ:TBH) and FibroBiologics, Inc. (NASDAQ:FBLG) on the RedChip Small Stocks,... ► Artikel lesen | |
| 11.07. | FibroBiologics, Inc.: FibroBiologics to Present at the Advanced Wound Care Summit USA | 2 | GlobeNewswire (USA) | ||
| 07.07. | FibroBiologics, Inc.: FibroBiologics' to Present at Exclusive Live Investor Webinar and Q&A Session on July 10 | 1 | GlobeNewswire (USA) | ||
| 03.07. | FibroBiologics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 03.07. | RedChip Companies, Inc.: Fathom Holdings and FibroBiologics Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV | 452 | ACCESS Newswire | ORLANDO, FLORIDA / ACCESS Newswire / July 3, 2025 / RedChip Companies will air interviews with Fathom Holdings, Inc. (Nasdaq:FTHM) and FibroBiologics, Inc. (Nasdaq:FBLG) on the RedChip Small Stocks... ► Artikel lesen | |
| 16.06. | FibroBiologics, Inc. - 8-K, Current Report | 2 | SEC Filings |
1 2 Weiter >>
39 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 90,50 | -0,60 % | PRESSESPIEGEL/Unternehmen: LEG, DEUTSCHE BAHN, FLINK, BIONTECH/CUREVAC, NEURAXPHARM | DJ PRESSESPIEGEL/Unternehmen
Die wirtschaftsrelevanten Themen aus den Medien, zusammengestellt von Dow Jones Newswires.
LEG - Der Chef des zweitgrößten deutschen Vermieters LEG, Lars von Lackum... ► Artikel lesen | |
| CUREVAC | 4,578 | -0,56 % | BioNTech startet milliardenschweres Umtauschangebot für CureVac-Aktien | BioNTech hat das öffentliche Umtauschangebot für alle ausstehenden Aktien von CureVac N.V. gestartet. Das Angebot basiert auf dem Kaufvertrag vom 12. Juni 2025 und sieht vor, dass jede CureVac-Aktie... ► Artikel lesen | |
| MODERNA | 22,870 | -0,76 % | Tesla- & IBM-Bilanzen enttäuschen - D-Wave, Moderna, Honeywell, T-Mobile US | Nach dem Rekordlauf vom Dienstag haben die Anleger an der Wall Street am Mittwoch Kasse gemacht. Der Dow Jones verlor zum Handelsschluss 0,71 Prozent. Besonders deutlich fiel die Korrektur im Technologiesektor... ► Artikel lesen | |
| NOVAVAX | 7,442 | -0,11 % | Novavax, Inc.: Novavax Executes Planned Site Consolidation, Further Reducing Cost Footprint in Line with Corporate Strategy | Agreements signed to transfer one U.S.-based facility and sell certain equipment netting $60 million in cash and resulting in future cash savings of $230 million... ► Artikel lesen | |
| NANOREPRO | 1,785 | +3,78 % | Original-Research: NanoRepro AG (von GBC AG): Kaufen | Original-Research: NanoRepro AG - von GBC AG
09.10.2025 / 12:00 CET/CEST
Veröffentlichung einer Research, übermittelt durch EQS News - ein Service der EQS Group.
Für den Inhalt der Mitteilung bzw.... ► Artikel lesen | |
| 4SC | 0,728 | -1,62 % | 4SC AG ringt um Zukunft nach schwerem Rückschlag | Das Biotech-Unternehmen 4SC AG (ISIN: DE000A3E5C40) aus Planegg-Martinsried steht an einem kritischen Wendepunkt. Nachdem die Europäische Arzneimittelbehörde EMA im Mai die Zulassung für das Krebsmedikament... ► Artikel lesen | |
| VIVOSIM LABS | 1,220 | -100,00 % | VivoSim Labs, Inc.: VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer | SAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim Labs"), a pharmaceutical and biotechnology services company that is focused on providing testing... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 2,100 | -3,67 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Inducement Grant Under Inducement Plan | PLYMOUTH MEETING, Pa., Oct. 2, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help... ► Artikel lesen | |
| INFLARX | 1,390 | -0,22 % | InflaRx N.V.: InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement | JENA, Germany, Sept. 12, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system (the "Company")... ► Artikel lesen | |
| SCORPIUS | 0,072 | 0,00 % | Scorpius Holdings, Inc. - 8-K, Current Report | ||
| DEFENCE THERAPEUTICS | 0,514 | -1,53 % | Defence Therapeutics Inc.: Defence to Present New Scientific Data on Its ADC-Enhancing Accum Technology at the World ADC Conference in San Diego, USA, November 4-5, 2025 | Montreal, Quebec--(Newsfile Corp. - October 23, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in drug... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 6,324 | +0,83 % | BioCryst Pharmaceuticals, Inc.: BioCryst to Present New Pediatric HAE Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting | ||
| DYNAVAX | 9,056 | +0,40 % | Dynavax Technologies: Dynavax Presents Positive Topline Data from Part 1 of Phase 1/2 Trial for Shingles Vaccine Candidate at IDWeek 2025 and Announces Initiation of Part 2 of Trial | Z-1018 demonstrates comparable antibody and CD4+ T-cell responses to Shingrix® with a favorable tolerability profile
Newly presented data outline robust... ► Artikel lesen | |
| IBIO | 1,060 | -2,75 % | Why Did iBio Shares Surge Over 11% In Pre-Market Trading? | ||
| REDHILL BIOPHARMA | 1,570 | 0,00 % | RedHill Biopharma Receives Nasdaq Staff Determination Notification | On October 16, 2025, the Company received a Staff Determination notification from The Nasdaq Stock Market LLC regarding continued non-compliance with the minimum... ► Artikel lesen |
FIBROBIOLOGICS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,004 (-1,08 %) liegt der Kurs bei 0,368 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu FIBROBIOLOGICS INC finden Sie auf Wallstreet Online.